<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors and Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>3109</td>
<td><strong>SPECIAL FEATURES</strong></td>
<td></td>
</tr>
<tr>
<td>3111</td>
<td><strong>Stearoyl Co-A Desaturase 1 as a ccRCC Therapeutic Target:</strong> Death by Stress</td>
<td>Janet Y. Leung and William Y. Kim. See related article by von Roemeling et al., Clin Cancer Res, vol. 19(9), p. 2368–80</td>
</tr>
<tr>
<td>3114</td>
<td><strong>Molecular Pathways:</strong> Extracting Medical Knowledge from High-Throughput Genomic Data</td>
<td>Theodore C. Goldstein, Evan O. Paull, Matthew J. Ellis, and Joshua M. Stuart.</td>
</tr>
</tbody>
</table>
Frequent Inactivation of Cysteine Dioxygenase Type 1 Contributes to Survival of Breast Cancer Cells and Resistance to Anthracyclines

Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia
Shaun Willimott, Daniel Beck, Matthew J. Ahearne, Victoria C. Adams, and Simon D. Wagner

Prolonged Inhibition of Glioblastoma Xenograft Initiation and Clonogenic Growth following In Vivo Notch Blockade
Qian Chu, Brent A. Orr, Samantha Semenkow, Eli E. Bar, and Charles G. Eberhart

Monoclonal Antibody against the Ectodomain of E-Cadherin (DECMA-1) Suppresses Breast Carcinogenesis: Involvement of the HER/PI3K/Akt/mTOR and IAP Pathways
Sabine M. Brouxhon, Stephanos Kyrkanides, Xiaofei Teng, Veena Raja, M. Kerry O'Banion, Robert Clarke, Stephen Byers, Andrew Silberfeld, Carmen Tornos, and Li Ma

Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network

EDNRB and DCC Salivary Rinse Hypermethylation Has a Similar Performance as Expert Clinical Examination in Discrimination of Oral Cancer/Dysplasia versus Benign Lesions

Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
Heidrun Gevensleben, Isaac Garcia-Murillas, Monika K. Graeser, Gaia Schiavon, Peter Osin, Marina Parton, Ian E. Smith, Alan Ashworth, and Nicholas C. Turner

PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer

IMAGING, DIAGNOSIS, PROGNOSIS

Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome
Katia Todorotti, Luca Agnelli, Sonia Fabris, Marta Lionetti, Giacomo Tsana, Laura Mosca, Luigia Lombardi, Vittina Grieco, Gabriella Bianchino, Fiorella D’Auria, Teodora Statuto, Carmela Mazzoccoli, Lucia De Luca, Maria Teresa Petrucci, Fortunato Morabito, Massimo Offidani, Francesco Di Raimondo, Antonietta Falcone, Paola Omede’, Pierfrancesco Tassone, Mario Boccadoro, Antonio Palumbo, Antonino Nerl, and Pellegrino Musto
CANCER THERAPY: CLINICAL

Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes

Carla Filì, Michele Malagola, Matilde Y. Follo, Carlo Finelli, Ilaria Iacobucci, Giovanni Martinelli, Federica Cattina, Cristina Clissa, Anna Candoni, Renato Fanin, Marco Gobbi, Monica Bocchia, Marzia Defina, Pierangelo Spedini, Cristina Skert, Lucia Manzoli, Lucio Cocco, and Domenico Russo

3309

A Review of Study Designs and Outcomes of Phase I Clinical Studies of Nanoparticle Agents Compared with Small-Molecule Anticancer Agents

Whitney P. Caron, Katherine P. Morgan, Beth A. Zamboni, and William C. Zamboni

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity


LETTERS TO THE EDITOR

Plasma MicroRNAs in Ovarian Cancer—Letter

Haifeng Qiu

Plasma MicroRNAs in Ovarian Cancer—Response

Xin Huang and Anda M. Vlad

RETRACTION

Retraction: Functional Characterization of the Bladder Cancer Marker, BLCA-4